ARNI & SGLT2 Inhibitors in HF

SECTION 1

Historical Context & The Unmet Need in Heart Failure

Heart failure (HF) has remained one of the most lethal and resource-intensive cardiovascular syndromes worldwide, with five-year mortality rates historically rivaling those of many cancers. For decades, the pharmacological management of heart failure with reduced ejection fraction (HFrEF) relied on neurohormonal blockade—specifically ACE inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, and mineralocorticoid receptor antagonists (MRAs). While these agents meaningfully reduced mortality, residual risk remained unacceptably high, prompting the search for therapies that could offer incremental survival benefit by targeting novel pathways. Two drug classes that emerged from this search—angiotensin receptor–neprilysin inhibitors (ARNIs) and sodium–glucose co-transporter 2 (SGLT2) inhibitors—fundamentally altered the treatment landscape and are now enshrined as pillars of guideline-directed medical therapy (GDMT).

1987

ACE Inhibitors Prove Mortality Benefit

The CONSENSUS trial demonstrated that enalapril reduced mortality by 40% in severe HF (NYHA IV), establishing RAAS blockade as the cornerstone of HF therapy and setting the benchmark for all future trials.

2000

Omapatrilat and the Neprilysin Concept

Omapatrilat, a dual ACE–neprilysin inhibitor, showed promise in the OVERTURE trial but was ultimately rejected by the FDA due to an unacceptable rate of angioedema, driven by excessive bradykinin accumulation from simultaneous ACE and neprilysin inhibition.

2014

PARADIGM-HF Validates Sacubitril/Valsartan

The landmark PARADIGM-HF trial showed that sacubitril/valsartan reduced cardiovascular death or HF hospitalization by 20% compared with enalapril, leading to the concept of ARNI therapy and a paradigm shift in HFrEF treatment.

2019

DAPA-HF Expands SGLT2i Beyond Diabetes

Dapagliflozin reduced the composite of worsening HF or CV death by 26% in patients with HFrEF regardless of diabetes status, establishing SGLT2 inhibitors as a new pillar of HF therapy independent of glycemic control.

2022

Four-Pillar GDMT Codified

Updated AHA/ACC/HFSA guidelines formalized the four-pillar approach: ARNI (or ACEi/ARB), beta-blocker, MRA, and SGLT2 inhibitor, with Class I recommendations for all four in HFrEF and SGLT2i receiving a Class IIa for HFpEF.

The central question driving these advances was deceptively simple: can we move beyond pure RAAS blockade and find complementary neurohormonal and metabolic pathways whose modulation further improves outcomes? The ARNI class answered this by simultaneously enhancing the natriuretic peptide system while blocking the deleterious effects of angiotensin II, and the SGLT2 inhibitors answered it through mechanisms that remain an area of active investigation—ranging from osmotic diuresis and improved cardiac energetics to attenuation of inflammation and cardiac fibrosis. Together, these two classes represent the most significant therapeutic advances in HF pharmacology in the past two decades.

SECTION 2

Core Pharmacological Principles

Understanding ARNI and SGLT2 inhibitor therapy in HF requires a firm grasp of several interconnected physiological and pharmacological principles. The failing heart triggers a cascade of neurohormonal activation—including the RAAS, sympathetic nervous system, and natriuretic peptide system—that is initially compensatory but ultimately maladaptive when sustained. Both drug classes act on distinct components of this neurohormonal milieu, and their mechanisms are largely complementary, which is why combining them within a four-pillar regimen yields additive benefits.

Neprilysin Inhibition

Neprilysin is a neutral endopeptidase that degrades several vasoactive peptides, including ANP, BNP, bradykinin, and adrenomedullin. Inhibiting neprilysin with sacubitril (via its active metabolite LBQ657) raises circulating natriuretic peptide levels, promoting natriuresis, vasodilation, and anti-fibrotic/anti-hypertrophic signaling through cGMP.

Angiotensin Receptor Blockade

Because neprilysin also degrades angiotensin II, standalone neprilysin inhibition can paradoxically raise angiotensin II levels. Pairing sacubitril with the ARB valsartan blocks the AT₁ receptor, countering any rise in angiotensin II and providing additive RAAS suppression without the angioedema risk of dual ACE/NEP inhibition.

SGLT2 Cotransporter Physiology

SGLT2 is a sodium–glucose cotransporter expressed in the S1 segment of the proximal convoluted tubule, responsible for reabsorbing approximately 90% of filtered glucose. Inhibiting SGLT2 with agents like dapagliflozin or empagliflozin induces glucosuria, natriuresis, and osmotic diuresis, reducing preload and intravascular volume.

Metabolic & Cardioprotective Effects of SGLT2i

Beyond hemodynamic effects, SGLT2 inhibitors shift myocardial substrate utilization toward ketone bodies (β-hydroxybutyrate), reduce oxidative stress and NLRP3 inflammasome activation, lower intraglomerular pressure via tubuloglomerular feedback, and attenuate cardiac fibrosis—all of which contribute to cardioprotection independent of glycemic control.

Complementary Neurohormonal Modulation

ARNI augments the counter-regulatory natriuretic peptide system while suppressing RAAS; SGLT2i reduces volume overload and improves metabolic efficiency. Neither drug class directly affects sympathetic tone (the target of beta-blockers) or mineralocorticoid signaling (the target of MRAs), which is why all four pillars are needed simultaneously.

✦ KEY TAKEAWAY

Think of HFrEF therapy like defending a castle under siege from four directions. An ACE inhibitor or ARB guards one gate (RAAS), beta-blockers guard another (sympathetic overdrive), and MRAs guard a third (aldosterone). But the castle has a fourth gate—volume overload, metabolic derangement, and inadequate protective peptide signaling. ARNI reinforces the natriuretic peptide defenses while maintaining RAAS blockade, and SGLT2 inhibitors drain the moat (volume) and reinforce the castle walls (metabolic resilience). You need all four gates defended simultaneously; leaving any unguarded allows the siege to continue.

SECTION 3

Mechanism of Action — Visual Overview

Left panel: sacubitril inhibits neprilysin to raise protective natriuretic peptides while valsartan blocks AT₁ receptors, together yielding vasodilation, natriuresis, and anti-remodeling effects. Right panel: SGLT2 inhibitors act at the proximal tubule to produce hemodynamic, metabolic, anti-inflammatory, and renoprotective effects that converge on reduced HF events—independent of glucose-lowering.

The diagram above highlights why an ARB rather than an ACE inhibitor was chosen for the ARNI combination. Neprilysin degrades bradykinin, and ACE does as well; blocking both enzymes simultaneously (as omapatrilat did) causes bradykinin to accumulate excessively, leading to life-threatening angioedema. Using an ARB instead of an ACE inhibitor avoids this safety hazard while still providing robust RAAS blockade at the receptor level. Notably, sacubitril/valsartan must not be co-administered with an ACE inhibitor, and a 36-hour washout period is required when switching from an ACEi to an ARNI to prevent overlapping bradykinin potentiation. On the right side of the diagram, notice that the SGLT2 inhibitor's benefits are truly pleiotropic—no single pathway fully accounts for the clinical benefit observed, and the relative contribution of each mechanism remains an active area of investigation.

SECTION 4

Pharmacokinetics, Pharmacodynamics & Dosing

Sacubitril/Valsartan (Entresto®) — Key PK/PD Parameters

Sacubitril/valsartan is formulated as the sodium salt complex of the sacubitril prodrug and valsartan in a 1:1 molar ratio. The approved dosage forms are expressed as sacubitril/valsartan mg (e.g., 24/26 mg, 49/51 mg, 97/103 mg). After oral ingestion, sacubitril undergoes esterase-mediated conversion to its active metabolite LBQ657, which achieves peak plasma concentration (T_max) at approximately 2 hours with an elimination half-life of roughly 11.5 hours. Valsartan reaches T_max at 1.5 hours with a half-life of approximately 9.9 hours. The different half-lives mean that with twice-daily dosing, both components achieve effective steady-state concentrations within 3 days. The drug is 94–97% protein-bound and is metabolized hepatically (CYP450 plays a minimal role), with elimination occurring renally (for LBQ657) and via biliary excretion (for valsartan).

ARNI TITRATION SEQUENCE

24/26 mg BID → 49/51 mg BID → 97/103 mg BID (target dose)

Double the dose every 2–4 weeks as tolerated. Monitor SBP (hold if < 100 mmHg), potassium, and serum creatinine at each step. The 36-hour ACEi washout must precede initiation.

SGLT2 Inhibitors — Key PK/PD Parameters

Both dapagliflozin (Farxiga®) and empagliflozin (Jardiance®) are orally bioavailable C-glucoside derivatives that competitively and reversibly inhibit SGLT2. Dapagliflozin has an oral bioavailability of approximately 78%, reaches T_max in 2 hours, and has a half-life of approximately 12.9 hours, supporting once-daily dosing. Empagliflozin has similar kinetics with a T_½ of approximately 12.4 hours. Both agents are primarily metabolized via UGT-mediated glucuronidation rather than CYP450 pathways, which minimizes drug-drug interactions—a clinically important advantage in the polypharmacy-heavy HF population. SGLT2 inhibitors induce a glycosuric effect of approximately 60–80 grams of glucose per day, but their cardiovascular benefits emerge within weeks and appear independent of HbA₁c reduction.

SGLT2i DOSING FOR HFrEF

Dapagliflozin 10 mg QD | Empagliflozin 10 mg QD

No dose titration required. Can be initiated at the target dose. May use if eGFR ≥ 20 mL/min/1.73 m² (per 2022 guidelines). Monitor for volume depletion, UTIs, and genital mycotic infections.

💊 CLINICAL PEARL

A major advantage of SGLT2 inhibitors in practice is the absence of a titration requirement. Unlike ARNI, beta-blockers, or MRAs—all of which demand gradual uptitration with monitoring—SGLT2 inhibitors can be started at their target dose of 10 mg once daily, making them an ideal 'first-start' agent in newly diagnosed HFrEF when clinicians aim to initiate all four pillars rapidly.

SECTION 5

Landmark Trials & Evidence Base

The clinical adoption of both ARNI and SGLT2 inhibitors in HF was driven by large, well-designed randomized controlled trials. Understanding the design, population, primary endpoints, and key results of these trials is essential for interpreting current guidelines and anticipating how future evidence might expand or refine indications.

Forest-plot–style summary of hazard ratios from landmark HF trials. All four trials demonstrated statistically significant reductions in their primary composite endpoints. Note that the comparator for PARADIGM-HF was active (enalapril), making its 20% relative risk reduction particularly impressive, while the SGLT2i trials used placebo comparators on top of standard-of-care background therapy.

Summary of Landmark Trials for ARNI and SGLT2 Inhibitors in Heart Failure

Trial	Drug / Comparator	Population	Primary Endpoint HR (95% CI)	Key Safety Signal
PARADIGM-HF	Sacubitril/valsartan vs. enalapril	HFrEF, LVEF ≤ 40%, NYHA II–IV, n = 8,442	0.80 (0.73–0.87), p < 0.001	More symptomatic hypotension (14% vs. 9%); less renal impairment and hyperkalemia vs. enalapril
DAPA-HF	Dapagliflozin 10 mg vs. placebo	HFrEF, LVEF ≤ 40%, NYHA II–IV, n = 4,744 (58% non-diabetic)	0.74 (0.65–0.85), p < 0.001	No increase in hypoglycemia or DKA; volume depletion similar to placebo
EMPEROR-Reduced	Empagliflozin 10 mg vs. placebo	HFrEF, LVEF ≤ 40%, NYHA II–IV, n = 3,730 (50% non-diabetic)	0.75 (0.65–0.86), p < 0.001	Uncomplicated genital infections more common; no DKA signal
EMPEROR-Preserved	Empagliflozin 10 mg vs. placebo	HFpEF, LVEF > 40%, NYHA II–IV, n = 5,988	0.79 (0.69–0.90), p < 0.001	Similar safety profile; benefit driven primarily by HF hospitalization reduction
DELIVER	Dapagliflozin 10 mg vs. placebo	HFmrEF/HFpEF, LVEF > 40%, n = 6,263	0.82 (0.73–0.92), p < 0.001	Confirmed SGLT2i benefit across the EF spectrum

Several observations merit emphasis. First, PARADIGM-HF compared sacubitril/valsartan against an active comparator (enalapril at 10 mg BID), meaning the ARNI's benefit represents true superiority over existing best-in-class RAAS blockade rather than superiority over placebo. Second, the SGLT2 inhibitor trials enrolled large proportions of non-diabetic patients and found consistent benefit regardless of baseline HbA₁c, definitively establishing these agents as HF drugs rather than merely diabetes drugs with cardiac side benefits. Third, the EMPEROR-Preserved and DELIVER trials extended the SGLT2i indication into HFpEF—a population for which, until these results, no pharmacotherapy had convincingly reduced the primary composite endpoint.

SECTION 6

Worked Example — Initiating Four-Pillar GDMT

Consider a clinical scenario in which you must systematically apply pharmacological principles to initiate and titrate guideline-directed medical therapy for a patient newly diagnosed with HFrEF. This worked example integrates mechanism of action knowledge, dosing protocols, and monitoring parameters into a clinical reasoning framework.

Case: 62-Year-Old with Newly Diagnosed HFrEF

Step 1 — Assess the Clinical ScenarioA 62-year-old man presents with NYHA Class III symptoms (dyspnea on minimal exertion, orthopnea). Echocardiogram shows LVEF of 28%. Labs: SBP 118 mmHg, HR 88 bpm, K⁺ 4.2 mEq/L, eGFR 55 mL/min/1.73 m², BNP 1,240 pg/mL, HbA₁c 6.1% (non-diabetic). He is on no HF medications and was previously taking lisinopril 10 mg daily for hypertension.

Diagnosis: HFrEF (LVEF 28%), NYHA III — all four pillars of GDMT are indicated

Step 2 — Plan ARNI Initiation (Requires ACEi Washout)Because the patient is currently on lisinopril (an ACE inhibitor), we must discontinue it and wait a minimum of 36 hours before starting sacubitril/valsartan to avoid the risk of angioedema from overlapping bradykinin potentiation. Given his SBP of 118 mmHg and eGFR of 55 (moderate renal impairment), we initiate ARNI at the lowest dose: sacubitril/valsartan 24/26 mg BID. The target dose is 97/103 mg BID, with uptitration every 2–4 weeks as tolerated.

Stop lisinopril → 36-hour washout → start sacubitril/valsartan 24/26 mg BID

Step 3 — Initiate SGLT2 Inhibitor (No Titration Needed)The patient's eGFR of 55 mL/min/1.73 m² is well above the threshold of 20 mL/min/1.73 m² for SGLT2i use in HF. We start dapagliflozin 10 mg QD (or empagliflozin 10 mg QD). No dose titration is required—this is the target dose from day one. We counsel the patient about genital hygiene to reduce the risk of mycotic infections and advise adequate hydration. Notably, this patient is non-diabetic; hypoglycemia risk is negligible because SGLT2 inhibitors do not stimulate insulin secretion.

Start dapagliflozin 10 mg QD immediately — full target dose from initiation

Step 4 — Initiate Beta-Blocker and MRASimultaneously (or within the first 1–2 weeks), we start a beta-blocker—carvedilol 3.125 mg BID (given NYHA III, start low)—and spironolactone 12.5 mg daily (K⁺ of 4.2 and eGFR 55 allow safe initiation). Both require titration: carvedilol toward 25 mg BID and spironolactone toward 25–50 mg daily. The modern approach favors rapid initiation of all four pillars at low doses rather than sequential uptitration of one agent at a time.

Start carvedilol 3.125 mg BID + spironolactone 12.5 mg QD → uptitrate both to target

Step 5 — Monitoring & Follow-Up StrategyAt the 2-week follow-up visit, check: SBP (must remain ≥ 100 mmHg to uptitrate ARNI), K⁺ (target < 5.0 mEq/L, especially with MRA), serum creatinine/eGFR, and symptoms. An initial 10–30% decline in eGFR with SGLT2i initiation is expected and reflects reduced intraglomerular pressure (analogous to the initial eGFR dip seen with ACEi/ARB)—it is generally not a reason to discontinue therapy. If SBP tolerates, double sacubitril/valsartan to 49/51 mg BID. Note that BNP levels may paradoxically rise with ARNI use because neprilysin inhibition prevents BNP degradation; NT-proBNP (which is not a neprilysin substrate) is the preferred biomarker for monitoring HF status during ARNI therapy.

Use NT-proBNP (not BNP) to monitor HF on ARNI. Expect initial eGFR dip with SGLT2i—do not discontinue.

SECTION 7

Comparative Pharmacology & Adverse Effect Profiles

A clinically useful exercise is to directly compare the ARNI and SGLT2 inhibitor classes across several dimensions—mechanism, titration burden, drug interactions, and adverse effects—to appreciate why they are complementary rather than interchangeable within the four-pillar framework.

Head-to-Head Comparison of ARNI vs. SGLT2 Inhibitor Classes

Feature	Sacubitril/Valsartan (ARNI)	Dapagliflozin / Empagliflozin (SGLT2i)
Primary Target	Neprilysin (sacubitril) + AT₁ receptor (valsartan)	SGLT2 cotransporter in PCT S1 segment
Mechanism Essence	↑ NP/cGMP signaling + ↓ Ang II/aldosterone axis	Glucosuria, natriuresis, osmotic diuresis, metabolic substrate shift, anti-inflammatory
Dose Titration	Required: 3 dose levels over 4–8 weeks	Not required: target dose from day 1
Key Contraindication	Concomitant ACEi use (36-hour washout required); history of angioedema	Type 1 diabetes (DKA risk); severe renal impairment historically, though threshold now eGFR ≥ 20
Principal Adverse Effects	Symptomatic hypotension, hyperkalemia (less than ACEi), angioedema (rare), dizziness	Genital mycotic infections, UTI, volume depletion, rare Fournier's gangrene, euglycemic DKA (primarily in T1DM)
Impact on Biomarkers	↑ BNP (because neprilysin degrades BNP); NT-proBNP remains reliable	↓ NT-proBNP; mild ↓ HbA₁c (0.2–0.5%); ↑ hematocrit (hemoconcentration)
CYP450 Interactions	Minimal; no significant CYP450 metabolism	Minimal; metabolized via UGT glucuronidation
Renal Threshold	Dose-adjust for eGFR < 30; use with caution	May initiate if eGFR ≥ 20 mL/min/1.73 m² (2022 guidelines)

✦ KEY TAKEAWAY

ARNI and SGLT2 inhibitors are not pharmacological substitutes—they attack different pathological axes of heart failure. ARNI amplifies the body's own counter-regulatory natriuretic peptide system while silencing the deleterious RAAS; SGLT2 inhibitors reshape hemodynamics, energetics, and inflammation through mechanisms that remain only partially understood. This mechanistic orthogonality is precisely why both classes are recommended together as pillars of GDMT: their benefits are additive because they do not overlap in mechanism or compete for the same therapeutic 'space.'

SECTION 8

Connection to Advanced Concepts & Emerging Frontiers

The success of ARNI and SGLT2 inhibitors has catalyzed a broader rethinking of HF pathophysiology and treatment strategy. Several advanced concepts and emerging therapeutic frontiers directly build upon the pharmacological principles underlying these two classes.

From Current Practice to Emerging Frontiers

Current Concept	Emerging Frontier / Advanced Application
ARNI in HFrEF (PARADIGM-HF)	ARNI in HFpEF: PARAGON-HF showed a near-significant benefit (HR 0.87, p = 0.06), with significant benefit in the subgroup with LVEF below-median, suggesting a role in HFmrEF and lower-range HFpEF
SGLT2i in chronic HF	SGLT2i in acute decompensated HF: EMPULSE trial showed empagliflozin initiated during hospitalization improved a hierarchical composite endpoint, supporting early in-hospital initiation
SGLT2i for cardiorenal protection	CREDENCE and DAPA-CKD trials demonstrated independent renal protective effects—slowing eGFR decline, reducing proteinuria—establishing SGLT2i as a kidney disease drug class and leading to CKD-specific indications regardless of diabetes
Four-pillar sequential initiation	Rapid-sequence or simultaneous initiation of all four GDMT pillars at low doses, with concurrent uptitration. The STRONG-HF trial supports intensive uptitration to target doses within 2 weeks, challenging the traditional slow, sequential approach
Neprilysin as a drug target	Dual endothelin/neprilysin inhibitors (e.g., sacubitril combined with endothelin receptor antagonists) are under investigation. Additionally, understanding neprilysin's role in amyloid-β degradation has raised questions about long-term ARNI use and Alzheimer's disease risk, though no signal has emerged in clinical data

The trajectory of SGLT2 inhibitor research is particularly notable for how it has expanded beyond its original indication. What began as an oral hypoglycemic agent for type 2 diabetes mellitus has now become a cornerstone of therapy for HFrEF, HFpEF, and CKD—three conditions that share overlapping pathophysiology involving hemodynamic stress, inflammation, fibrosis, and metabolic derangement. Future investigations will likely explore SGLT2i in additional phenotypes such as atrial fibrillation, obesity-related cardiomyopathy, and post-cardiac surgery recovery. Similarly, the concept of augmenting endogenous cardioprotective peptide systems—pioneered by ARNI—may inspire next-generation therapies that modulate other vasoactive peptides such as apelin, relaxin, or adrenomedullin.

SECTION 9

Practice Problems

PROBLEM 1 — CONCEPTUAL

Explain why sacubitril is paired with an ARB (valsartan) rather than an ACE inhibitor in the ARNI formulation, despite the fact that both ARBs and ACE inhibitors block the RAAS. What specific pharmacological hazard does this design choice avoid?

PROBLEM 2 — BASIC CALCULATION

In the DAPA-HF trial, the hazard ratio for the primary composite endpoint (CV death or worsening HF) was 0.74. If the event rate in the placebo group was 21.2% over the median follow-up of 18.2 months, estimate the absolute risk reduction (ARR) and the number needed to treat (NNT) over the trial duration.

PROBLEM 3 — INTERMEDIATE

A 58-year-old woman with HFrEF (LVEF 30%) and type 2 diabetes (HbA₁c 7.8%) is currently on enalapril 10 mg BID, carvedilol 25 mg BID, and spironolactone 25 mg QD. Her SBP is 108 mmHg, K⁺ is 4.8 mEq/L, and eGFR is 38 mL/min/1.73 m². Her cardiologist wants to add an SGLT2 inhibitor and switch from enalapril to sacubitril/valsartan. Outline the sequence of medication changes and identify which monitoring parameters require the closest attention.

PROBLEM 4 — APPLIED

A hospital formulary committee is debating whether to preferentially stock dapagliflozin or empagliflozin for their HF population. Using your knowledge of the evidence base, identify key similarities and differences between the two agents in terms of trial data across HFrEF, HFpEF, and CKD. Which agent, if either, has a broader approved indication profile as of 2023?

PROBLEM 5 — CRITICAL THINKING

The cardioprotective benefits of SGLT2 inhibitors appear disproportionately large relative to their modest hemodynamic effects (mild reduction in preload and blood pressure). Construct a hypothesis-driven argument for why the non-hemodynamic mechanisms—specifically the metabolic substrate shift toward ketone utilization and the anti-inflammatory effects via NLRP3 inflammasome suppression—may be the primary drivers of clinical benefit in HFrEF. What type of study design would you propose to test this hypothesis?

SUMMARY

Lesson Summary

Heart failure with reduced ejection fraction is now treated with a four-pillar GDMT framework comprising an ARNI (or ACEi/ARB), beta-blocker, MRA, and SGLT2 inhibitor. Sacubitril/valsartan (ARNI) uniquely combines neprilysin inhibition—which raises protective natriuretic peptide levels and enhances cGMP-mediated vasodilation, natriuresis, and anti-fibrotic signaling—with AT₁ receptor blockade to suppress the deleterious effects of angiotensin II. The PARADIGM-HF trial demonstrated a 20% relative risk reduction in cardiovascular death or HF hospitalization compared with enalapril. Critically, an ARB rather than an ACEi was chosen for the combination to avoid excessive bradykinin accumulation and angioedema, and a 36-hour ACEi washout is mandatory before ARNI initiation. When monitoring patients on ARNI, use NT-proBNP rather than BNP because neprilysin inhibition elevates BNP levels independent of HF status.

SGLT2 inhibitors (dapagliflozin, empagliflozin) block the sodium–glucose cotransporter in the proximal tubule, producing pleiotropic benefits that include osmotic diuresis, metabolic substrate shift toward ketone bodies, NLRP3 inflammasome suppression, reduced intraglomerular pressure via tubuloglomerular feedback, and attenuation of cardiac fibrosis. The DAPA-HF and EMPEROR-Reduced trials showed ≈25% relative risk reductions in the primary composite endpoint regardless of diabetes status. SGLT2 inhibitors require no dose titration, can be initiated at the target dose of 10 mg once daily, and have a favorable safety profile with minimal CYP450 interactions. Their indications have expanded to include HFpEF and CKD, making them among the most versatile cardiorenal drugs in modern medicine. Together with ARNI, these agents embody the principle that optimal HF therapy requires simultaneous modulation of multiple neurohormonal and metabolic pathways.